State KS
Clinical Trials in Kansas
Recruiting clinical trials with at least one study location in Kansas. Data updated daily from ClinicalTrials.gov.
Top Conditions in Kansas
Cardiovascular Disease (3)Stage IVB Prostate Cancer AJCC v8 (3)Hypertension (3)Oral Cavity Squamous Cell Carcinoma (2)Stage I Lip and Oral Cavity Cancer AJCC v8 (2)Stage II Lip and Oral Cavity Cancer AJCC v8 (2)Pancreatic Cancer (2)Multiple Myeloma (2)Acute Ischemic Stroke (2)Stage IV Lung Cancer AJCC v8 (2)Idiopathic Pulmonary Fibrosis (2)Obesity (2)
Frequently Asked Questions — Clinical Trials in Kansas
How many clinical trials are currently recruiting in Kansas?
ClinicalMetric currently tracks 146 actively recruiting clinical trials with at least one location in Kansas. The total number of registered studies—including active but not currently enrolling trials—is 146. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Kansas?
Kansas hosts clinical trials across a broad range of medical conditions, including Cardiovascular Disease, Stage IVB Prostate Cancer AJCC v8, Hypertension, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Kansas serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Kansas?
To join a clinical trial in Kansas, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Kansas maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Kansas
NCT07140783 Phase 3
Recruiting
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Kerato...
Condition
Vision Loss Night
Enrollment
200 pts
Location
United States
Sponsor
Ocuphire Pharma, Inc.
NCT06561386 Phase 3
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs...
Condition
Non-small Cell Lung Cancer
Enrollment
1,000 pts
Location
United States, Argentina, Australia
Sponsor
Bristol-Myers Squibb
NCT06016842 Phase 3
Recruiting
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Chol...
Condition
Primary Biliary Cholangitis (PBC)
Enrollment
276 pts
Location
United States, Argentina, Australia
Sponsor
Ipsen
NCT06858579 Phase 3
Recruiting
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic In...
Condition
Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment
256 pts
Location
United States, Argentina, Australia
Sponsor
Dianthus Therapeutics
NCT06532279 Phase 2
Recruiting
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the ...
Condition
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Enrollment
98 pts
Location
United States
Sponsor
NRG Oncology
NCT06472245 Phase 3
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung...
Condition
Patients With Non-Small Cell Lung Cancer
Enrollment
363 pts
Location
United States, Belgium, Canada
Sponsor
OSE Immunotherapeutics
NCT06736717 Phase 1, Phase 2
Recruiting
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced P...
Condition
Pancreatic Cancer
Enrollment
21 pts
Location
United States
Sponsor
University of Kansas Medical C
NCT05201781 Phase 4
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autole...
Condition
Multiple Myeloma
Enrollment
295 pts
Location
United States, Belgium, China
Sponsor
Janssen Research & Development
NCT05594563 Phase 2
Recruiting
TArgeting Type 1 Diabetes Using POLyamines (TADPOL)
Condition
Type 1 Diabetes
Enrollment
81 pts
Location
United States
Sponsor
Emily K. Sims
NCT07115940 N/A
Recruiting
Medical Management With Endovascular Thrombectomy Versus Medical Management Alon...
Condition
Acute Ischemic Stroke
Enrollment
408 pts
Location
United States
Sponsor
Amrou Sarraj
NCT04661358 Phase 3
Recruiting
Fenofibrate for Prevention of DR Worsening
Condition
Diabetic Retinopathy
Enrollment
560 pts
Location
United States
Sponsor
Jaeb Center for Health Researc
NCT04181060 Phase 3
Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With E...
Condition
Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Enrollment
300 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT05913908 N/A
Recruiting
EFS of the DUO System for Tricuspid Regurgitation
Condition
Tricuspid Regurgitation
Enrollment
15 pts
Location
United States, Poland
Sponsor
CroiValve Limited
NCT06770582 Phase 2
Recruiting
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Ther...
Condition
Non-Muscle Invasive Bladder Urothelial Carcinoma
Enrollment
160 pts
Location
United States, Canada
Sponsor
National Cancer Institute (NCI
NCT07118215 Phase 1
Recruiting
A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofe...
Condition
Healthy Volunteers
Enrollment
60 pts
Location
United States
Sponsor
Karuna Therapeutics, Inc., a B
NCT04752774 Phase 1, Phase 2
Recruiting
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With...
Condition
Spasticity
Enrollment
240 pts
Location
United States, Austria, Bulgaria
Sponsor
Ipsen
NCT05301140 N/A
Recruiting
Vivistim Registry for Paired VNS Therapy (GRASP)
Condition
Upper Extremity Problem
Enrollment
1,000 pts
Location
United States
Sponsor
MicroTransponder Inc.
NCT06967805 Phase 2
Recruiting
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis...
Condition
Idiopathic Pulmonary Fibrosis
Enrollment
164 pts
Location
United States, Argentina, Australia
Sponsor
Mediar Therapeutics
NCT06143956 Phase 2
Recruiting
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices ...
Condition
Obesity
Enrollment
1,217 pts
Location
United States, Argentina
Sponsor
Eli Lilly and Company
NCT06926920 Phase 1, Phase 2
Recruiting
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Pa...
Condition
Triple Negative Breast Cancer
Enrollment
100 pts
Location
United States, Australia, South Korea
Sponsor
Gilead Sciences
NCT05611242 Phase 3
Recruiting
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlu...
Condition
Acute Ischemic Stroke
Enrollment
404 pts
Location
United States
Sponsor
Mercy Health Ohio
NCT06944522 Phase 3
Recruiting
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Ha...
Condition
Parkinsons Disease (PD)
Enrollment
102 pts
Location
United States, Australia, Canada
Sponsor
BlueRock Therapeutics
NCT02781883 Phase 2
Recruiting
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in ...
Condition
Acute Myeloid Leukemia (AML)
Enrollment
108 pts
Location
United States
Sponsor
Bio-Path Holdings, Inc.
NCT06123182 N/A
Recruiting
Guided Episodic Future Thinking to Increase Physical Activity Adherence and Prom...
Condition
Exercise Training
Enrollment
160 pts
Location
United States
Sponsor
University of Kansas Medical C
NCT07583186 N/A
Recruiting
Maternal Intake of Eggs and Infant Neurodevelopment
Condition
Pregnancy Related
Enrollment
100 pts
Location
United States
Sponsor
University of Kansas Medical C
Page 1 of 6 — 146 trials total
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology